Vena Cava Occlusion for Cardiac Preload Reduction

ChangeBridge: Patent Grants - Medical Devices (A61M)

Published April 7th, 2026

Detected April 7th, 2026

Summary

USPTO granted Patent US12594416B2 to Magenta Medical Ltd covering apparatus and methods for reducing cardiac preload by partially occluding the vena cava at an infra-renal location. The patent claims monitoring physiological parameters including venous pressures and cardiac dimensions to modulate occlusion extent responsively. The patent contains 17 claims.

View original document View source feed page

What changed

USPTO issued US12594416B2 to Magenta Medical Ltd on April 7, 2026, granting exclusive rights to a cardiac preload reduction system using partial vena cava occlusion at an infra-renal location. The patented technology monitors multiple physiological parameters including lower body venous pressure, central venous pressure, renal venous pressure, cardiac diameter/volume, and arterial hemodynamics to responsively modulate occlusion extent.

For medical device manufacturers developing products for heart failure management, cardiac unloading, or hemodynamic monitoring, this patent establishes intellectual property boundaries. Competitors must design around these claims or seek licensing. Healthcare providers using such devices should verify proper IP licensing arrangements through manufacturers. The patent's CPC classifications indicate applications in artificial heart systems and cardiovascular catheters.

What to do next

Monitor for updates

Source document (simplified)

← USPTO Patent Grants

Vena caval occlusion

Grant US12594416B2 Kind: B2 Apr 07, 2026

Assignee

MAGENTA MEDICAL LTD

Inventors

Yosi Tuval, Ehud Schwammenthal, Daniel Glozman, Gad Lubinsky

Abstract

Apparatus and methods are described including reducing cardiac preload of a subject by partially occluding a vena cava of the subject at an infra-renal location. One or more physiological parameters of the subject are monitored, the one or more physiological parameters including lower body venous pressure, central venous pressure, central venous blood flow, renal venous pressure, cardiac diameter, cardiac volume, arterial pressure, and/or arterial blood flow. An extent to which the vena cava is occluded at the infra-renal location is modulated, responsively to the one or more physiological parameters. Other applications are also described.